A 28-year-old woman with a 6-year history of heroin dependence presents to a de-addiction clinic requesting long-term maintenance therapy. She is currently using 2–3 grams of heroin daily and reports multiple failed attempts at abstinence. She is pregnant (8 weeks gestation) and wishes to continue her pregnancy. Which maintenance agent is most appropriate for this patient?

## Opioid Maintenance Therapy in Pregnancy **Key Point:** Buprenorphine is the preferred maintenance agent in pregnant women with opioid use disorder because it has a lower risk of neonatal opioid withdrawal syndrome (NOWS) and better fetal safety profile compared to methadone. ### Pregnancy-Specific Considerations | Agent | Pregnancy Safety | NOWS Risk | Fetal Outcome | Clinical Use | |-------|------------------|-----------|---------------|---------------| | **Buprenorphine** | Preferred (Category 3) | Lower (~40–60%) | Better; less placental transfer | First-line in pregnancy | | **Methadone** | Acceptable but higher risk | Higher (~60–90%) | More severe NOWS; more placental transfer | Second-line; if already stable | | **Naltrexone** | Contraindicated | N/A | High relapse risk; teratogenic data limited | Avoid in pregnancy | | **Clonidine** | Not indicated for maintenance | N/A | Hypotension risk to mother and fetus | Symptomatic use only | **High-Yield:** Buprenorphine reduces the incidence and severity of neonatal opioid withdrawal syndrome (NOWS) by ~50% compared to methadone, making it the evidence-based choice for pregnant women. ### Mechanism of Buprenorphine Advantage 1. **Partial agonist activity** → lower placental transfer than full agonists (methadone) 2. **High receptor binding affinity** → less fluctuation in maternal levels → more stable fetal exposure 3. **Lower lipophilicity** → reduced fetal accumulation 4. **Neonatal outcomes:** Shorter duration of NOWS, fewer days requiring pharmacotherapy, lower seizure risk **Clinical Pearl:** Even if a patient is already stable on methadone, pregnancy is an indication to consider switching to buprenorphine (with careful tapering and cross-induction) to reduce fetal and neonatal risks. ### Why Other Options Are Suboptimal **Methadone (Option B):** - Full mu-opioid agonist with high placental transfer - Higher incidence of severe NOWS (60–90% of exposed neonates) - Longer duration of neonatal withdrawal (may require 2–4 weeks of treatment) - Still acceptable if patient already stable, but buprenorphine is preferred for new inductions **Naltrexone (Option C):** - Opioid antagonist; high relapse risk in pregnancy (patient will seek heroin) - Limited safety data in pregnancy; not recommended - Precipitates withdrawal if given to opioid-dependent patient **Clonidine (Option D):** - Not a maintenance agent; only symptomatic relief of withdrawal - Does not prevent relapse or maintain abstinence - Maternal hypotension risk; not suitable for long-term use in pregnancy **Mnemonic:** **BUPRENORPHINE = Best Useful Partial agonist Reduces Neonatal Opioid Withdrawal In Pregnant Expectant mothers** — captures both the drug class and pregnancy indication.